Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).

O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).

Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).

Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).

Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).

Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).

Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).

Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).

Voltà-Durán E., Parladé E., Serna N., Villaverde A., Vazquez E., Unzueta U.. Endosomal escape for cell-targeted proteins. Going out after going in. BIOTECHNOLOGY ADVANCES. 2023; 63DOI:10.1016/j.biotechadv.2023.108103. PMID:36702197. IF:12.100(Q1/1D).

Rueda A., Mendoza J.I., Alba-Castellon L., Parladé E., Voltà-Durán E., Paez D., Aviño A., Eritja R., Vázquez E., Villaverde A., Mangues R., Unzueta U.. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). Science China-Materials. 2023; 66(10)DOI:10.1007/s40843-023-2571-6. PMID:. IF:6.800(Q1/3D).

Mosquera-Orgueira, A, Perez-Encinas, M, Hernandez-Sanchez, A, Gonzalez-Martinez, T, Arellano-Rodrigo, E, Martinez-Elicegui, J, Villaverde-Ramiro, A, Raya, JM, Ayala, R, Ferrer-Marin, F, Fox, ML, Velez, P, Mora, E, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Angona, A, Cuevas, B, Senin, MA, Ramirez-Payer, A, Ramirez, MJ, Perez-Lopez, R, de Villambrosia, SG, Martinez-Valverde, C, Gomez-Casares, MT, Garcia-Hernandez, C, Gasior, M, Bellosillo, B, Steegmann, JL, Alvarez-Larran, A, Hernandez-Rivas, JM, Hernandez-Boluda, JC. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000818. PMID:36570691. IF:11.900(Q1/1D).

Marin-Bejar O., Romero-Moya D., Rodriguez-Ubreva J., Distefano M., Lessi F., Aretini P., Liquori A., Castaño J., Kozyra E., Kotmayer L., Bueno C., Cervera J., Rodriguez-Gallego J.C., Nomdedeu J.F., Murillo-Sanjuán L., De Heredia C.D., Pérez-Martinez A., López-Cadenas F., Martínez-Laperche C., Dorado-Herrero N., Marco F.M., Prósper F., Menendez P., Valcárcel D., Ballestar E., Bödör C., Bigas A., Catalá A., Wlodarski M.W., Giorgetti A.. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. HAEMATOLOGICA. 2023; 108(9)DOI:10.3324/haematol.2022.282305. PMID:36815365. IF:10.100(Q1/2D).

Frezza A.M., Stacchiotti S., Chibon F., Coindre, JM, Italiano A., Romagnosa C., Bagué S., Dei Tos A.P., Braglia L., Palmerini E., Quagliuolo V., Broto J.M., Pousa, AL, Grignani G., Brunello A., Blay, JY, Beveridge R.D., Lugowska I., Lesluyes T., Maestro R., Merlo F.D., Casali P.G., Gronchi A.. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2)DOI:10.1002/cam4.5015. PMID:35848358. IF:2.900(Q2/5D).

Medina-Gutiérrez E., García-León A., Gallardo A., Álamo P., Alba-Castellón L., Unzueta U., Villaverde A., Vázquez E., Casanova I., Mangues R.. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers. 2023; 15(1)DOI:10.3390/cancers15010085. PMID:36612081. IF:4.500(Q1/3D).

Cosio B.G., Shafiek H., Iglesias A., Mosteiro M., Gonzalez-Piñeiro A., Rodríguez M., García-Cosío M., Busto E., Martin J., Mejías L., Benito A., López Vilaro L., Gómez C.. Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(8)DOI:10.1016/j.arbres.2023.05.014. PMID:37414638. IF:8.700(Q1/1D).

Chiesa-Estomba C.M., González-García J.A., Genden E.M., Piazza C., Guntinas-Lichius O., Vander-Poorten V., Kowalski L.P., López F., Quer M., Rodrigo J.P., Sanabria Á., Fernández-Álvarez V., Suárez C., Cohen O., de Bree R., Shaha A.R., Makitie, AA, Ferlito A.. Complications related to the Cook-Swarz implantable Doppler probe use in head and neck microvascular reconstruction: a systematic review. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2023; 280(1)DOI:10.1007/s00405-022-07577-3. PMID:35941283. IF:1.900(Q2/3D).

Sansa A., Valero C., Holgado A., Vásquez R., Quer M., Patel S.G., León X.. External validation of the H-index (host index) in patients with head and neck squamous cell carcinomas. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2023; 45(1)DOI:10.1002/hed.27224. PMID:36225167. IF:2.400(Q1/2D).

León X., Pujals G., Sauter B., Neumann E., Pujol A., Quer M.. Differential characteristics of patients with squamous cell carcinoma of the head and neck with no history of tobacco or alcohol use. Acta Otorrinolaringologica Espanola. 2023; 74(1)DOI:10.1016/j.otorri.2022.02.003. PMID:36709798. IF:(Q/D).

Rodrigo J.P., Sánchez-Canteli M., Triantafyllou A., de Bree R., Mäkitie A.A., Franchi A., Hellquist H., Saba N.F., Stenman G., Takes R.P., Valero C., Zidar N., Ferlito A.. Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis †. Cancers. 2023; 15(3)DOI:10.3390/cancers15030802. PMID:36765760. IF:4.500(Q1/3D).